pISSN 1226-6051
eISSN 2508-786X

Table. 2.

Table. 2.

Comparison studies related to the effects of Pramipexole or Ropinirole on impulse control disorder incidences

Reference Study design Country Total sample size (# of exposed) Distribution of male Mean age Outcome type Treatment duration Mean treatment dose ICD incidences Crude odds ratio [95% confidence interval] P-value
Bayard et al. (2013)16) Case-control France 89 (50) 31% 57.2 years Binge eating;Pathological gambling;Trichotillomania;Kleptomania;Compulsive shopping;Hypersexuality 11 months (median) PRX:0.36 mg/d;ROP:0.75 mg/d Exposed:2.0%Non-exposed:2.6% 0.776 [0.05-12.8] 0.86
Heim et al. (2016)17) Case-control USA 58 (36) 48% 62.2 years Binge eating;Punding;Pathological gambling;Hypersexuality;Compulsive shopping;Hoarding Not reported with ICD:1.23 mg/dwithout ICD:0.58 mg/d Exposed:36.1%Non-exposed:45.5% 0.67 [0.13-1.99] 0.48
Voon et al. (2011)15) Cross-sectional Germany 140 (78) 30% 56.2 years Binge eating;Punding;Pathological gambling;Hypersexuality;Compulsive shopping Not reported with ICD: 0.64mg/dwithout ICD:0.27 mg/d Exposed:7.7%Non-exposed:6.5% 1.2 [ 0.3-4.5] 0.77
Montagna et al. (2011)18) Randomized controlled trial Germany 403 (203) 30% 55.6 years Not reported 12 weeks (mean) Not reported Not reported Not applicable
Lipford et al. (2012)19) Cohort study USA 50 (50) 19% 60.0 years Binge eating;Pathological gambling;Hypersexuality;Compulsive shopping 8 years (mean) with ICD: 1.33mg/d;without ICDnot reported Exposed:10.0%Non-exposed:0.0% Not applicable

ICD: Impulse control disorder; PRX: Pramipexole; ROP: Ropinirole

Korean J Clin Pharm 2020;30:250-8 https://doi.org/10.24304/kjcp.2020.30.4.250
© 2020 Korean J Clin Pharm